HYFTOR™ is the first and only topical medication approved by the FDA to treat facial angiofibroma associated with tuberous sclerosis complex (TSC) in adults and children 6 years and older.
HYFTOR™ is a clear gel that contains an mTOR inhibitor.
HYFTOR™ should be applied to the skin of the face affected with angiofibroma twice daily, in the morning and at bedtime. The maximum recommended daily dosage is1:
HYFTOR is an mTOR inhibitor immunosuppressant indicated for the treatment of facial angiofibroma associated with tuberous sclerosis in adults and pediatric patients 6 years of age and older.
CONTRAINDICATIONS
HYFTOR is contraindicated in patients with a history of hypersensitivity to sirolimus or any other component of HYFTOR.
WARNINGS AND PRECAUTIONS
ADVERSE REACTIONS
The most common adverse reactions (≥1%) are dry skin, application site irritation, pruritus, acne, acneiform dermatitis, ocular hyperemia, skin hemorrhage, and skin irritation.
USE IN SPECIFIC POPULATIONS
Please see full Prescribing Information for additional safety information.
© 2022 Nobelpharma America, LLC. All rights reserved.
HYF-PRO-1215-v1
HYFTOR is an mTOR inhibitor immunosuppressant indicated for the treatment of facial angiofibroma associated with tuberous sclerosis in adults and pediatric patients 6 years of age and older.
CONTRAINDICATIONS
HYFTOR is contraindicated in patients with a history of hypersensitivity to sirolimus or any other component of HYFTOR. READ MORE >>
By submitting your email address, you are opting in and may be provided with online advertisements or communications on Nobelpharma or third-party websites that are tailored to you, for example, on the basis of nonidentifying information or of your web browsing activity. When a Nobelpharma communication is delivered to you, you will see information about how to opt-out. By clicking the arrow, you agree and understand that your information will be governed by our Privacy Policy.
Link pending once FDA approval comes in…